Compare Jones Lang LaSalle Inc (JLL) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Nuwellis Inc — how do they compare? Jones Lang LaSalle Inc trades at $303.6 (market cap $13.65B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Jones Lang LaSalle Inc is far larger — about 6204.5× Nuwellis Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Nuwellis Inc for 26 Days on average.
| JLL | NUWE | |
|---|---|---|
Market Cap | $13.65B | $2.20M |
Volume | 465,758 | 121,544 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $146.65 |
52-Week Low | $280.16 | $0.68 |
Typical Hold Time | 71 Days | 26 Days |
Enterprise Value | $16.41B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $296.66, down 2.29% today, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $5.26 beating expectations by 15%. Revenue growth accelerated to $26.12 billion in 2025, while net income margin improved to 3.64%. Recent acquisitions and financing deals demonstrate continued expansion in key markets.
The stock presents a compelling value opportunity with a P/E of 14.23 and P/S of 0.52 below industry averages. Analyst consensus targets $450.50, implying 52% upside potential. Key risks include real estate market cyclicality and execution challenges in global expansion. Strong cash flow generation and institutional buying support the bullish fundamental case despite near-term technical weakness.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
